Ocera Therapeutics (OCRX) Completes Enrollment in Phase 2a Study of OCR-002 to Treat Acute Liver Failure
Tweet Send to a Friend
Ocera Therapeutics, Inc. (NASDAQ: OCRX), today announced completion of enrollment in STOP-ALF, a Phase 2a clinical trial to evaluate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
